Converting Promising Science Into Partnerable Assets
Perago Bio is a virtual pipeline biopharma company that turns underdeveloped therapeutic programs into partnerable clinical-stage assets. We acquire or license high-potential programs, advance them through stage-gated translational and early clinical development, and defer traditional company formation until the data supports it.
A New Architecture for Drug Development
Translate & De-Risk
We take programs from candidate translation through early clinical de-risking — IND enablement, Phase 1, and proof of concept — acting as operator across every program. Perago provides the operating engine required to turn promising programs into partnerable clinical-stage assets.
Lean by Design
A centralized development engine — scientific strategy, regulatory, CMC, and BD — shared across the portfolio and executed through a curated CRO, CDMO, and specialist consulting network. Institutional-grade execution without the overhead.
BD Optionality at Every Gate
Fast, capital-efficient de-risking creates multiple points of business development optionality. At each milestone, assets can be out-licensed, partnered, or acquired — or continued through a spin-out if the data warrants it.
We Find Science Where Capital Has Not Followed
Academia
Early-Stage Biotech
Pharma Divestitures
Capital-Constrained Companies
Development Progression
One Engine. Many Programs.
Perago acts as the internal development team across every program in the portfolio. We centralize scientific strategy, regulatory, CMC, and BD at the company level — executing through a CRO, CDMO, and specialist consulting network we direct. NewCo formation is deferred until after clinical de-risking, so capital goes to science, not structure.
Each program is managed as a separate cost center with predefined go/no-go criteria at every stage gate.
Shared Capabilities
Multiple Paths to Value Creation
At Ph1 or early POC, assets are positioned for out-licensing, a pharma development or capital partnership, or outright acquisition. Where no transaction is available at that stage, the program is spun out into a standalone NewCo and capitalized through VC syndication to continue through Phase 2.
Out-Licensing
Development Partnership
Capital Partnership
Acquisition
NewCo + VC Syndication
Proceeds from asset monetizations may be distributed to shareholders and/or reinvested into the pipeline, subject to board-approved reserves.
Work With Us
We are actively seeking high-potential therapeutic programs from academia, early-stage biotech, pharma divestitures, and capital-constrained companies.
[email protected]→Invest in Perago
Perago Bio offers investors exposure to a focused pipeline of therapeutic assets developed under institutional-grade capital discipline.
[email protected]→